WeChatshare
Vaccine Innovation Forum 2023

You can share it to WeChat via the Qr code.

Eventsshare
Vaccine Innovation Forum 2023

Enter the applet sharing event using WeChat scan.

About VIF

Vaccine Innovation Forum (VIF) World 2024 to be held in China aims to bring together experts, researchers, policymakers, and industry leaders from around the world to collaborate and advance the field of vaccine development and immunization. Vaccines have played a crucial role in preventing and controlling infectious diseases, and they continue to be instrumental in safeguarding global public health. China, with its significant contributions to vaccine research, development, and production, serves as an ideal host for this prestigious event.

 

As the world faces emerging infectious threats and ongoing health challenges, it is crucial to foster international cooperation and knowledge exchange in the realm of vaccine development. This conference will serve as a platform to share cutting-edge research findings, discuss innovative vaccine technologies, address global immunization gaps, and promote equitable vaccine distribution.



图片1.png


For more information: pls contact Sam Li   sam.li@chstone-events.com, or 86-13482341046



Schedule
2023-06-29
2023-06-30
2023-06-29
08:50 -17:30
Main Conference
2023-06-29
08:55-09:00

Opening Remark

Speaker
Vaccine Innovation Forum 2023
Bin Wang
Chief Scientific Adviser, Advacccine
2023-06-29
09:00-09:45

Next generation nucleic acid approaches for therapeutics / immune therapy of disease and induction of protective immunity

Speaker
Vaccine Innovation Forum 2023
David Weiner
Executive Vice President, The Wistar Institute/ Director, Vaccine & Immunotherapy Center /Professor & WW Smith Distinguished Chair in Cancer /Research Professor Emeritus, University of Pennsylvania,US.
2023-06-29
09:45-10:10

Biomimetic synthetic vaccines: from artificial particles to natural particle chassis

Speaker
Vaccine Innovation Forum 2023
Guanghui Ma
Academician, PI, Institute of Process, CAS
2023-06-29
10:10-10:35

Next generation mucosal vaccine development

  1. Current Vaccine Problem

  2. Introducing Inhalation Vaccine

  3. Some Highlight Result from Clinical and Real World Study

Speaker
Vaccine Innovation Forum 2023
Chunlin Xin
VP, Cansino Biologics
2023-06-29
10:35-11:00

Tea Break

2023-06-29
11:00-11:25

mRNA Vaccine Development: COVID and Beyond

Speaker
Vaccine Innovation Forum 2023
Kiat Ruxrungtham
Director of Chula Vaccine Research Center, Chulalongkorn University
2023-06-29
11:25-11:50

Developing RNA vaccines and therapeutics after COVID-19

Speaker
Vaccine Innovation Forum 2023
Yuanqing Liu
CSO China, Immorna Biotherapeutics
2023-06-29
11:50-12:15

Advancing global vaccine R&D franchise for respiratory diseases

Respiratory diseases including low air track infections and related chronical degenerative diseases became leading causes of death globally. Recently, WHO announced the end of the Covid pandemics which lasted over 3 years. SCB-2019 is a protein subunit vaccine with adjuvant against Covid-19. With trials enrolling over 37500 human subjects, SCB-2019 was demonstrated efficacious across various subgroups including adults over 60, adolescence and young adults, either used for primary immunization or as a booster. SCB-2019 can provide protection against pre-omicron and some omicron strains of Covid-19. With EUA of SCB-2019, Clover successfully grew into a full-fledged biopharma with proprietary trimer-tag platform, China-centric discovery and commercial teams, and global development and regulatory capabilities. To meet the need for protection against Covid-19 XBB strains, Clover developed both SCB-2023 including a XBB.1.5 antigen and raced to deliver them before the next wave of pandemics in this year. Along with Covid-19, spread of other respiratory infectious diseases, such as influenza and RSV, also imposed serious threats on human health. Clover in-licensed a Flu vaccine which will hit the market in the 2nd half of this year. Based on trimer-tag and unique stabilizing mutations, RSV vaccine is also under preclinical development with desirable immunogenicity data. Clover is committed to provide comprehensive solutions for vaccination against respiratory diseases.

Speaker
Vaccine Innovation Forum 2023
Wei Tan
SVP, Head of China Research and External Collaboration, Clover Biopharmaceutical
2023-06-29
12:15-13:30

Networking Lunch

2023-06-29
13:30-13:30

Moderator

Speaker
Vaccine Innovation Forum 2023
Dexiang Chen
President& General Manager, Maxvax
2023-06-29
13:30-13:55

Clinical development for the first approved mRNA vaccine in China

Speaker
Vaccine Innovation Forum 2023
Yuanzheng Qiu
General Manager of Vaccine Clinical Center, CSPC Group
2023-06-29
13:55-14:20

Advancing Global Health Through Innovative Vaccine Research and Development: Lessons Learned from Hilleman

Speaker
Vaccine Innovation Forum 2023
Alain Bouckenooghe
CSO, Hilleman Laboratories
2023-06-29
14:20-14:45

Empowering mRNA therapy development with innovative technologies

Speaker
Vaccine Innovation Forum 2023
Haifa Shen
Co-Founder&CTO, Stemirna
2023-06-29
14:45-15:10

Decoding adjuvant technologies in recombinant vaccine development

Speaker
Vaccine Innovation Forum 2023
Dexiang Chen
President& General Manager, Maxvax
2023-06-29
15:10-15:35

Tea Break

2023-06-29
15:35-16:00

Research and development of kits for vaccine quantification and immunogenicity evaluatio

Speaker
Vaccine Innovation Forum 2023
Le Sun
CEO & President of AbMax Biotechnology
2023-06-29
16:00-16:25

Challenges and opportunities: Advancing Chinese vaccine products to the global market

Speaker
Vaccine Innovation Forum 2023
Tianping Wang
Director of International regulatory Affairs, Sinovac Biotech
2023-06-29
16:25-16:50

Nanoparticulate Delivery of Subunit Antigens and Molecular Adjuvants

The vaccines of subunits, peptides, and mRNA represent new generation of vaccination technology for fighting infectious diseases and cancers. However, these biomacromolecules face the problems of degradation, transportation to target tissue and cells, and cellular uptake, which are the obstacles of their technology translation. Delivery technology based on materials and nanoparticular engineering becomes “last mile” of clinical application of novel vaccines. In this talk, I will present our research on nanovaccines by delivering subunits and adjuvants for eliciting potent humoral and cellular response. We have applied both biocompatible materials and engineered fabricating technologies to improve lymph node targeting and retention, and in turn the performance of the novel nanovaccines, which were evaluated in EV71, EBV and HB associated diseases. 

Speaker
Vaccine Innovation Forum 2023
Yongming Chen
Professor, Sun Yat-sen University
2023-06-29
16:50-17:15

Intranasal Immunization: Device and Formulation Promises and Challenges

Speaker
Vaccine Innovation Forum 2023
Julie D. Suman
Vice President of Scientific Affairs, Aptar Pharma
Vaccine Innovation Forum 2023
Nektaria Karavas
Global BD Director, Aptar Pharma
2023-06-29
17:15-17:15

End of Day 1

2023-06-30
09:00 -15:30
Main Conference
2023-06-30
09:00-09:00

Moderator

Speaker
Vaccine Innovation Forum 2023
Jeff Zhu
CEO, Ruizhou Bio
2023-06-30
09:00-09:25

Microneedle as a powerful delivery tool for DNA vaccination

Speaker
Vaccine Innovation Forum 2023
Bin Wang
Chief Scientific Adviser, Advacccine
2023-06-30
09:25-09:50

Vaccine development and immunology: from Zika to COVID-19

Speaker
Vaccine Innovation Forum 2023
Lianpan Dai
PI, The Institute of Microbiology, CAS
2023-06-30
09:50-10:15

Addressing IP challenges for RNA-based vaccine development

Dan will provide an in-depth discussion relating to the IP, litigation and competitive landscape in the mRNA and lipid nanoparticle space including recent trends and related analyses.

Speaker
Vaccine Innovation Forum 2023
Dan Shores
Partner, Rothwell Figg
2023-06-30
10:15-10:40

Novel self-assembled RNA nanoparticles for vaccination and therapy

After the successful development of lipid nanoparticles (LNPs) comprising messenger RNA (mRNA) for vaccination against Covid-19 the interest in mRNA and nanoparticle systems for various therapeutic applications has surged tremendously.

As delivery systems, currently LNPs, which are manufactured by a specific protocol with a defined mixture of four lipids are center of attention. However, there are several other nanoparticle formats which have demonstrated to be promising as delivery systems for RNA and other drugs.

Here some concepts for nanoparticle engineering based on lipids and polymers are presented, which allow for tailoring of the delivers system according to type of (RNA) cargo, application route and the intended therapeutic intervention.


Speaker
Vaccine Innovation Forum 2023
Heinrich Hass
EX-VP, RNA Formulation&Drug Delivery, BioNtech
2023-06-30
10:40-11:05

Tea Break

2023-06-30
11:05-11:30

Development of polyvalent pneumococcal conjugate vaccine against pneumococcal diseases

Streptococcus pneumoniae is a leading pathogen commonly colonized in human upper respiratory tract. Pneumococcal infection may cause meningitis, bacteremia, pneumonia, and acute otitis media, especially in susceptible populations. Pneumococcal vaccine has been proved as an effective approach to combat the pneumococcal disease. However, due to emerging of new pneumococcus serotypes and diverse epidemiology across the world, development of more effective vaccines to provide a much wider protection becomes necessary. In this presentation, I will give a summary on the development progress of polyvalent pneumococcal conjugate vaccines worldwide.

Speaker
Vaccine Innovation Forum 2023
Jeff Zhu
CEO, Ruizhou Bio
2023-06-30
11:30-11:55

Russia& CIS: vaccine market highlights & entry models

Russia&CIS vaccine markets:dynamics and structure

Overall pharma trends in Russia and development of governmental support 

Vaccine market regulatory background

Market entry models and cooperation opportunities

Nanolek as a potential partner


Speaker
Vaccine Innovation Forum 2023
Privalova Arina
Director, Strategic Development, Nanolek
2023-06-30
11:55-13:00

Networking Lunch

2023-06-30
13:00-13:00

Moderator

Speaker
Vaccine Innovation Forum 2023
Alex Li
COO, Axter Therapeutics
2023-06-30
13:00-13:25

Convacell – second generation vaccine against COVID-19

Speaker
Vaccine Innovation Forum 2023
Sergey Arakelov
Sci Dir., St. Petersburg Scientific Research Institute of Vaccines and Sera, FMBA,RU
2023-06-30
13:25-13:50

Plant-based vaccine development

Baiya Phytopharm, company introduction

Baiya pharming process, Plant-based vaccine, and therapeutic protein.

Baiya’s plant-based Covid-19 vaccine development during the pandemic.

Future for Plant-based technology platform.


Speaker
Vaccine Innovation Forum 2023
Jompong Champaiboon
COO,Baiya Phytopharm
2023-06-30
13:50-14:15

Targeted LNP in cancer vaccine development

Speaker
Vaccine Innovation Forum 2023
Alex Li
COO, Axter Therapeutics
2023-06-30
14:15-14:40

Structure-based vaccine development

Speaker
Vaccine Innovation Forum 2023
Shaowei Li
Professor, Xiamen University
2023-06-30
14:40-15:05

Challenges and opportunities for novel mRNA therapy development 

Speaker
Vaccine Innovation Forum 2023
Xiangrong Song
Co-Founder, Westgene
2023-06-30
15:05-15:45

Panel discussion: The future of vaccine development

Speaker
Vaccine Innovation Forum 2023
Jompong Champaiboon
COO,Baiya Phytopharm
Vaccine Innovation Forum 2023
Shaowei Li
Professor, Xiamen University
Vaccine Innovation Forum 2023
Xiangrong Song
Co-Founder, Westgene
Vaccine Innovation Forum 2023
Alex Li
COO, Axter Therapeutics
Vaccine Innovation Forum 2023
Sergey Arakelov
Sci Dir., St. Petersburg Scientific Research Institute of Vaccines and Sera, FMBA,RU

Opening Remark

Vaccine Innovation Forum 2023
Bin Wang
Chief Scientific Adviser, Advacccine
Dr. Bin Wang is the Co-founder, Chairman of Advaccine Biotechnology Co LTD. He is also holding a distinguished professor position at the Fudan University School of Basic Medical Sciences and serves as the chairman for the Nucleic Acid Vaccines branch of the Chinese Vaccine Society. His research area is focused on the effects of therapeutic vaccination to activate T cells and the mechanism of immune regulations. He has developed novel adjuvants and recombinant vaccines, novel DNA vaccine delivery, and led to several developed vaccines being tested in human clinical trials. He received his Ph.D. from the Cincinnati Children's Hospital at the University of Cincinnati School of Medicine in 1990. He completed his postdoc training in virology and immunology at the Wistar Institute in 1992 in Philadelphia. He became an instructor and assistant professor at the University of Pennsylvania Medical School from 1993 to 1998. He was a professor and served as the Chairman of the Department of Microbiology and Immunology for six years at the College of Biological Sciences, China Agricultural University before he joined Fudan University. He was one of the very early DNA vaccine technology inventors in the 90’s and performed the first-in-human DNA vaccine trials in 1994-1996. He has been involved in several clinical trials of therapeutic vaccines against chronic HBV infections in recent years and invented a novel prophylactic RSV vaccine currently under clinical phase II testing. He has published over 160 peer-review articles and awarded 35 US and 30 Chinese patents. He serves as an editorial board member for several international journals and executive member in several professional societies.

Next generation nucleic acid approaches for therapeutics / immune therapy of disease and induction of protective immunity

Vaccine Innovation Forum 2023
David Weiner
Executive Vice President, The Wistar Institute/ Director, Vaccine & Immunotherapy Center /Professor & WW Smith Distinguished Chair in Cancer /Research Professor Emeritus, University of Pennsylvania,US.

Biomimetic synthetic vaccines: from artificial particles to natural particle chassis

Vaccine Innovation Forum 2023
Guanghui Ma
Academician, PI, Institute of Process, CAS
Guanghui Ma is a professor of the State Key Laboratory of Biochemical Engineering (SKLBCE), Institute of Process Engineering (IPE). She is an academician of CAS in China and AIMBE fellow. She is serving as Director of the State Key Laboratory of Biochemical Engineering. She received Bachelor degree from Gunma University, Master and PhD degrees from Tokyo Institute of Technology, respectively. She joined SKLBCE as a professor in 2001 and was promoted to the director in 2012. Her research interests focus on the preparation of uniform microspheres and microcapsules and their applications in biochemical engineering and biomedicine engineering, such as biochemical separation media, drug carriers, vaccine adjuvants (vaccine delivery systems), microcarriers for cell culture, and enzyme immobilization carriers. She has published over 500 papers, including Nat. Mater., Nat. Nanotechnol. Nat. Biomed. Eng., Nat. Commun., Sci. Adv., JACS, Adv. Mater., etc. She has more than 90 patents authorized, the technology and products have been commercialized in companies, and have been used in more than 500 affiliations in the world. She has received the State National Invention Award (2nd Class; 2009), the Beijing Science and Technology Award (1st Class; 2005), the Basic Research Achievement Award (1st Class prise of Science and Technology Award; 2020) of the Chemical Industry and Engineering Society of China, and Natural Science Award (1st Class; 2020) of the Chinese Society of Particuology.

Next generation mucosal vaccine development

Vaccine Innovation Forum 2023
Chunlin Xin
VP, Cansino Biologics
Mr. Chunlin Xin is the Vice President of CanSino Biologics, where he currently oversees External R&D and scientific affairs. With over 20 years of experience in the biotech industry, Mr. Xin previously served as the Oncology Biomarker technical leader at the Novartis BioMedical Research Institute in the United States and China. He has also worked as a technical officer at the National Research Institute of Canada and as a senior scientist at the Merck Canada Research Institute. Mr. Xin graduated from the Virology Institute at the CDC China and spent five years as a visiting scholar at the University of North Carolina in the United States. In 2017, he joined CanSino as Senior Director of R&D, where he was responsible for designing and developing new vaccines and exploring and establishing new technology platforms. Most recently, Mr. Xin has played a lead role in assisting many developing countries in establishing COVID-19 vaccine manufacturing facilities through tech transfer.

Tea Break

mRNA Vaccine Development: COVID and Beyond

Vaccine Innovation Forum 2023
Kiat Ruxrungtham
Director of Chula Vaccine Research Center, Chulalongkorn University
Kiat Ruxrungtham, is a Professor of Medicine, Department of Medicine , Faculty of Medicine, Chulalongkorn University; and Scientific Chair of the Chula Vaccine Research Center (ChulaVRC); and Director of the Covid19 Vaccine Development Program, ChulaVRC. He is providing teaching and patient care on Allergy -Clinical Immunology and HIV Medicine at the King Chulalongkorn Memorial Hospital, Faculty of Medicine, Chulalongkorn University; and is mentoring junior researchers on HIV medicine at HIVNAT, TRCARC; vaccine and Immunology (at Chula Vaccine Research Center); and also on clinical trials. He is currently leading the Chula-Covid19 mRNA vaccine development program at ChulaVRC. Honors: He has received several awards: 2006 Outstanding Internist Award on Medical Academy, Royal College of Physicians, Thailand 2007 Outstanding Researcher Award, and the Highest Citation Award, Chulalongkorn University, Bangkok, Thailand 2011 Senior Research Scholar Award, the Thailand Research Fund 2011 Outstanding Researcher Award, National Research Council, Thailand 2015 Senior Research Scholar Award, the Thailand Research Fund 2015 Outstanding Research Award, the Thailand Research Fund 2022 A Royal Award “Contributors to the development of the country’s vaccines” from Her Royal Highness Princess Maha Chakri Sirindhorn at the 10th Vaccination Conference Publications: He has published more than 370 peer review papers on HIV, immunology, allergy, and vaccine. Contributions to national and international academics and professional organization: 1. Former President of the Allergy, Asthma and Immunology Association, Thailand (AAIAT) 2. Former President of the Thai AIDS Society (TAS) 3. Co-chair of the Co-chair of the APAACI and APAAAPARI 2018, Bangkok, Thailand 4. Co-chair of the World Allergy Congress 2023, Bangkok, Thailand 5. Chief-editor, Asian Pacific Journal of Allergy and Immunology (APJAI)

Developing RNA vaccines and therapeutics after COVID-19

Vaccine Innovation Forum 2023
Yuanqing Liu
CSO China, Immorna Biotherapeutics
Dr. Liu Yuanqing graduated from Shanghai Medical College of Fudan University and was a surgeon at Shanghai Zhongshan Hospital. He completed his PhD in Vrije Universiteit Brussel in Belgium and was one of the pioneers on myeloid-derived suppressors in tumors. He was previously a senior research lead at Sanofi Pasteur French headquarter, where he contributed to various vaccine projects, including cancer vaccines, vaccines against infectious diseases, pediatric vaccines, adjuvants, etc. Dr. Liu is an industry veteran with extensive experience in the development of innovative vaccines for international market. He was a member of the EU Innovative Medicine Initiative. Since 2021, he has been the Chief Scientific Officer of Immorna Biotechnology. He is based in Shanghai where Immorna has established a high-standard R&D site aiming to accelerate the development of mRNA vaccines and drugs in China.

Advancing global vaccine R&D franchise for respiratory diseases

Vaccine Innovation Forum 2023
Wei Tan
SVP, Head of China Research and External Collaboration, Clover Biopharmaceutical
Dr. Tan is responsible for drug discovery, preclinical development, translation research and external collaboration in China. Dr. Tan got his Ph.D. in Molecular Medicine from UT Health Science Center San Antonio and received his Postdoctoral training with Dr. Michael Karin at UC San Diego. Dr. Tan worked in Pfizer and Novartis for 9 years, specialized in drug discovery and translational research, bridging preclinical research to early clinical trials. Dr. Tan worked at Biosion Biotech and Coherent Biopharma before he joined Clover. Dr. Tan was selected as Jiangsu Innovation and Entrepreneur Talent and Suzhou Innovation and Entrepreneur Leading Talent.

Networking Lunch

Moderator

Vaccine Innovation Forum 2023
Dexiang Chen
President& General Manager, Maxvax
Dexiang Chen, Doctor of Immunology, Mississippi State University, has been engaged in the development of vaccines and vaccine adjuvants in Pfizer, Novartis and PATH scientific and technological organizations for more than 30 years, and has presided over a number of major international public health special projects funded by international organizations, foundations and national governments. Among the more than 20 infectious disease vaccine development projects presided over and participated in, many products have been listed globally. Dr. Chen Dexiang has published more than 60 vaccine-related academic papers in world-class academic journals such as Science and Nature Medicine.

Clinical development for the first approved mRNA vaccine in China

Vaccine Innovation Forum 2023
Yuanzheng Qiu
General Manager of Vaccine Clinical Center, CSPC Group
Dr. Qiu is the General Manager of Vaccine Clinical Center of CSPC Group. He joined the vaccine industry in 2005 and has been engaged in vaccine early stage R&D, clinical research and medical affairs for nearly 18 years. He has served in Beijing Institute of Biological Products, Sinovac Biotech, GlaxoSmithKline, Sanofi Pasteur, Merck Sharp & Dohme and Fosun Pharmaceuticals, where he was responsible for the early development of pneumococcal conjugate vaccine and Hib vaccine, and registration clinical trials with human avian influenza vaccine (H5N1), influenza A/H1N1 vaccine, DTaP-based combined vaccines, meningococcal conjugate vaccine, MMR varicella combined vaccine, polio inactivated vaccine, rotavirus vaccine, HPV vaccine, and SARS-CoV-2 mRNA vaccine. He was also responsible for the post-marketing clinical research and medical support for various vaccines. He is now working for CSPC Group and is responsible for the clinical studies of the vaccine product line.

Advancing Global Health Through Innovative Vaccine Research and Development: Lessons Learned from Hilleman

Vaccine Innovation Forum 2023
Alain Bouckenooghe
CSO, Hilleman Laboratories
Dr Alain Bouckenooghe is currently the Chief Scientific Officer at Hilleman Laboratories where he is leading the R&D department of this biotech company. He has been working in the pharmaceutical industry over 20 years, mostly in vaccine R&D but also in regulatory and medical affairs. Alain obtained his Medical Degree at the Catholic University of Leuven, Belgium. Upon graduation as MD he worked for several years in a rural assignment as a District Medical Officer under the Ministry of Health of Zambia. Subsequently, he completed his residency in Internal Medicine at the University of Texas, Houston. He has a Master of Public Health degree from the UT School of Public Health, Houston TX, and completed a Fellowship in Adult Infectious Diseases at Baylor College of Medicine, Houston TX. Alain held several academic positions during this time in the Department of Medicine at Baylor College. After initial industry experience with MSD and GlaxoSmithKline Biologicals, he joined Sanofi Pasteur in December 2006 to 2018, covering various responsibilities over time, including Regional Head of Clinical R&D Asia Pacific, Regional Head Medical Affairs, and R&D Partnership lead in Asia. Alain joined MSD in 2018 as Associate VP leading the respiratory franchise in Global Clinical Development. Alain feels very fortunate and honoured to be part of the Hilleman Laboratories team aiming to provide effective and affordable solutions for Global Health problems especially those impacting lower and middle income countries.

Empowering mRNA therapy development with innovative technologies

Vaccine Innovation Forum 2023
Haifa Shen
Co-Founder&CTO, Stemirna
Dr. Shen Haifa is co-founder and CTO of StemiRNA Therapeutics. He received his PhD degree from the Graduate School of Biomedical Sciences, the University of Texas/ M D Anderson Cancer Center in 1997, and completed his post-doctoral training at National Cancer Institute in 2001. He then joined the biopharmaceutical industry and worked there for eight years on cancer drug discovery and development. He went back to academia afterwards, focusing his research on drug design and drug delivery platforms. Dr. Shen was professor at Houston Methodist Hospital and founding director of the Innovative Therapeutics program at Houston Methodist Cancer Center, Weill Cornell Medical College of Cornell University. Dr. Shen and his group have published more than 110 peer-reviewed research articles including those in Nature, Nature Biotechnology, and Science Immunology, and have over 10 patents and patent applications.

Decoding adjuvant technologies in recombinant vaccine development

Vaccine Innovation Forum 2023
Dexiang Chen
President& General Manager, Maxvax
Dexiang Chen, Doctor of Immunology, Mississippi State University, has been engaged in the development of vaccines and vaccine adjuvants in Pfizer, Novartis and PATH scientific and technological organizations for more than 30 years, and has presided over a number of major international public health special projects funded by international organizations, foundations and national governments. Among the more than 20 infectious disease vaccine development projects presided over and participated in, many products have been listed globally. Dr. Chen Dexiang has published more than 60 vaccine-related academic papers in world-class academic journals such as Science and Nature Medicine.

Tea Break

Research and development of kits for vaccine quantification and immunogenicity evaluatio

Vaccine Innovation Forum 2023
Le Sun
CEO & President of AbMax Biotechnology
Dr. Sun, CEO & President of AbMax Biotechnology, Inc., Thousand Talent of Beijing, Adjunct Prof. of Beijing Normal University. He received his PhD in biochemistry from Tsinghua Univ. in 1989 and finished his postdoctoral study in Dr. David Barnes’s lab at Oregon State Univ. He has more than 30 yrs experience in antibody-based research and drug development. He was Director of R& D at Upstate Biotechnology Inc., a market leader in the research reagent sector. In 2000, as co-founder and the President, he started A&G Pharmaceutical in Baltimore, created the record of “Generation of mAb in 28 days” and received $2.5 M investment from MedImmune in 2001. In 2004, he started Welson Pharmaceuticals working on antibody drug conjugate, now has one leading candidate in co-development with a Chinese Pharma. In 2006, he started AbMax as a Biotech CRO, established the largest collection of mAbs against infectious diseases. Using AbEpiMax, the ONLY B cell-epitope identification program, and AbADCCZero, IP-protected De-ADCC technology, his team is developing 15+ Bio-Betters of Block-burst antibody drugs for I/O and auot-immune diseases. He has published 40+ papers on journals such as Nature Med., Nature Genetics, Immunity, Development Cell, etc.

Challenges and opportunities: Advancing Chinese vaccine products to the global market

Vaccine Innovation Forum 2023
Tianping Wang
Director of International regulatory Affairs, Sinovac Biotech
Tianping WANG, graduated from Renmin University of China with a master's degree, Director of International Regulatory Affairs, Group Quality Department Manager of Sinovac Biotech Ltd. Leading person in passing WHO PQ/EUL for four vaccines and obtaining nearly 300 international regulatory approvals in more than 40 countries for multiple vaccines. Coauthor of WHO Vaccine Prequalification Guidance. Responsible for promoting key projects such as COVID-19 overseas clinical trials and technical licensing, and participating in drawing the blueprint of international development strategy for Sinovac.

Nanoparticulate Delivery of Subunit Antigens and Molecular Adjuvants

Vaccine Innovation Forum 2023
Yongming Chen
Professor, Sun Yat-sen University
Yongming Chen received his Ph.D. on polymer science in 1993 from Nankai University. From 1994 to 1998, he was Postdoctoral Researcher and later Research Assistant at the Institute of Chemistry, CAS. Then he spent the period 1998−2001 as Postdoctoral Researcher in University of Düsseldorf and University of Mainz. Since 2001, Chen was Professor at the Institute of Chemistry CAS. He moved to Sun Yat-sen University in 2013. He obtained “Distinguished Young Scholars” by National Science Foundation of China (2006). He served for Polymer, an Elsevier journal, as an Associate Editor during 2007 to 2018. He also was in Advisory Board Panel of Macromolecules and ACS Macro Letters, the ACS Publication. Professor Chen’s research interests are in the areas of biomaterials chemistry and biomaterials application in delivery of proteins and nucleic acids, specifically application in immune attenuation. He has published over 260 research articles in Science Advances, Nature Communication, Biomaterials, Nano Letters et al and obtained 10 more licenced patents.

Intranasal Immunization: Device and Formulation Promises and Challenges

Vaccine Innovation Forum 2023
Julie D. Suman
Vice President of Scientific Affairs, Aptar Pharma
Dr. Julie D. Suman is the Vice President of Scientific Affairs for Aptar Pharma. She manages strategic scientific planning and Aptar’s Scientific Advisory Board. Dr. Suman is also the co-founder of Next Breath. She holds a B.S. in Pharmacy from Duquesne University (1996) and a Ph.D. in Pharmaceutical Sciences from the University of Maryland, Baltimore (2002). Dr. Suman serves on the External Advisory Committee of the New South Wales RNA Production and Research Network. In addition, she is a co-editor for Respiratory Drug Delivery Proceedings, an international symposium, and an an Affiliate Assistant Professor in the Department of Pharmaceutics, School of Pharmacy, Virginia Commonwealth University. Dr. Suman is the Past-Chair of the AAPS Inhalation Technology Focus Group. Dr. Suman is also a member of the Parental Drug Association Visible Particulate Taskforce. She is a licensed Maryland pharmacist. Dr. Suman has published her research in peer-reviewed journals and has been presented during podium sessions at international meetings, the FDA Topics in Bioequivalence Seminar Series and has been an invited speaker at ANVISA in Brazil. Dr. Suman’s doctoral research, which focused on the relationship between in vitro tests for nasal sprays and in vivo deposition, has been recognized for excellence by a research award presented at the International Society for Aerosols in Medicine, 2001. In 2008, Dr. Suman received an award from the Greater Baltimore Committee for Entrepreneurial Spirit.
Vaccine Innovation Forum 2023
Nektaria Karavas
Global BD Director, Aptar Pharma
Nektaria Karavas is the Global Director of Business Development for Nasal Vaccines, Antivirals and Immuno-stimulants at Aptar Pharma. Ms. Karavas joined Aptar Pharma in 2004 and has held various commercial roles executing long-term strategy within key customer and global accounts in North America focusing on nasal drug delivery. She has contributed to multiple nasal development programs, supported commercial scale up and product launches for New Drug Applications (NDA) using an Aptar delivery device for key pharmaceutical clients across different therapeutic indications. Nektaria holds a Bachelor of Science from McGill University, Montreal, Canada

End of Day 1

Moderator

Vaccine Innovation Forum 2023
Jeff Zhu
CEO, Ruizhou Bio
Dr. Jeff Zhu is the founder and CEO of Shanghai Reinovax Biologics co., Ltd., a fast-growing biotech company focusing on discovery and development of innovative vaccines and other biologics. Dr. Zhu has over 20 years’ industrial experience on discovery and development of small molecules, recombinant proteins, antibodies and vaccines from the early discovery to clinical trials. He played an important role in moving multiple drug candidates from the initiation to the clinical trial stage during his 13-year tenure at Pfizer’s R & D center in San Diego. Dr. Zhu moved back to China in 2011, and served as CSO and head of the R & D at Hualan Biological Engineering Inc., and two years later worked as senior director and department head in USP, Shanghai. Dr. Zhu published earned his Ph.D. degree on biological sciences from UC, Irvine, M.S. degree on biochemistry from Georgetown university, and B.S. degree on chemistry from Tsinghua university.

Microneedle as a powerful delivery tool for DNA vaccination

Vaccine Innovation Forum 2023
Bin Wang
Chief Scientific Adviser, Advacccine
Dr. Bin Wang is the Co-founder, Chairman of Advaccine Biotechnology Co LTD. He is also holding a distinguished professor position at the Fudan University School of Basic Medical Sciences and serves as the chairman for the Nucleic Acid Vaccines branch of the Chinese Vaccine Society. His research area is focused on the effects of therapeutic vaccination to activate T cells and the mechanism of immune regulations. He has developed novel adjuvants and recombinant vaccines, novel DNA vaccine delivery, and led to several developed vaccines being tested in human clinical trials. He received his Ph.D. from the Cincinnati Children's Hospital at the University of Cincinnati School of Medicine in 1990. He completed his postdoc training in virology and immunology at the Wistar Institute in 1992 in Philadelphia. He became an instructor and assistant professor at the University of Pennsylvania Medical School from 1993 to 1998. He was a professor and served as the Chairman of the Department of Microbiology and Immunology for six years at the College of Biological Sciences, China Agricultural University before he joined Fudan University. He was one of the very early DNA vaccine technology inventors in the 90’s and performed the first-in-human DNA vaccine trials in 1994-1996. He has been involved in several clinical trials of therapeutic vaccines against chronic HBV infections in recent years and invented a novel prophylactic RSV vaccine currently under clinical phase II testing. He has published over 160 peer-review articles and awarded 35 US and 30 Chinese patents. He serves as an editorial board member for several international journals and executive member in several professional societies.

Vaccine development and immunology: from Zika to COVID-19

Vaccine Innovation Forum 2023
Lianpan Dai
PI, The Institute of Microbiology, CAS
Lianpan Dai, PhD, Principal Investigator at Institute of Microbiology, Chinese Academy of Sciences. He received his doctor's degree from Technical University of Munich (TUM), Germany. His research is mainly focused on the design and development of novel vaccines against major pathogens and the mechanism of protective immune response. Important research and translational achievements have been made in the research and development of vaccines against coronaviruses, Zika virus and other emerging infectious diseases, among which the recombinant protein subunit COVID-19 vaccine has been approved for use in many countries. The results are published as first/corresponding authors in the journals including Cell, The New England Journal of Medicine, Nature Immunology, Nature Reviews Immunology, Cell Host & Microbe. He is supported by the National Science Fund for Excellent Young Scholars, and is the winner of VCANBIO Award for Biosciences and Medicine, excellent member of the Innovation Promotion Association of Chinese Academy of Sciences, and the Young Scholar Award of Chinese Society of Immunology.

Addressing IP challenges for RNA-based vaccine development

Vaccine Innovation Forum 2023
Dan Shores
Partner, Rothwell Figg
Dan Shores is a Partner at Rothwell Figg and a founder of its Boston, Massachusetts office. He has an extensive background in IP law in the biotech space and has been practicing in that space during the entirely of his 17-year career including in matters relating to small molecules, biosimilars, mRNA, LNP, and oligonucleotide technologies. Dan is passionate about helping his clients build robust patent portfolios, litigate matters (both as plaintiffs and defendants in the U.S. District Courts and in IPR and other post-grant proceedings), protect trade secrets, negotiate strategic collaborations, conduct due diligence and landscape investigations, and prepare for success in funding rounds and exits. Dan is a problem-solver who excels at deciphering key translational aspects of a broad array of technologies to maximize leverage in the context of clients’ desired implementation of such technologies whether as participants in dynamic markets or as first movers. Dan is a registered patent attorney licensed to practice before the U.S. Patent and Trademark Office. He is a member of the bars of the Supreme Court of the United States, United States Court of Appeals for the Federal Circuit, and United States District Court for the District of Massachusetts.

Novel self-assembled RNA nanoparticles for vaccination and therapy

Vaccine Innovation Forum 2023
Heinrich Hass
EX-VP, RNA Formulation&Drug Delivery, BioNtech
Heinrich Haas, Department of Biopharmaceutics and Pharmaceutical Technology Johannes Gutenberg-Universität, Mainz Mainz, Germany. Ph.D. in the group of Prof. Dr. Helmuth Möhwald at Johannes-Gutenberg Universität Mainz. Researched lipid membranes and organized bio-molecular systems. In pharmaceutical industry (Munich Biotech, Medigene, BioNTech) developed different types of nanoparticle products to clinical stage. Focus on advanced approaches for nanoparticle development and control.

Tea Break

Development of polyvalent pneumococcal conjugate vaccine against pneumococcal diseases

Vaccine Innovation Forum 2023
Jeff Zhu
CEO, Ruizhou Bio
Dr. Jeff Zhu is the founder and CEO of Shanghai Reinovax Biologics co., Ltd., a fast-growing biotech company focusing on discovery and development of innovative vaccines and other biologics. Dr. Zhu has over 20 years’ industrial experience on discovery and development of small molecules, recombinant proteins, antibodies and vaccines from the early discovery to clinical trials. He played an important role in moving multiple drug candidates from the initiation to the clinical trial stage during his 13-year tenure at Pfizer’s R & D center in San Diego. Dr. Zhu moved back to China in 2011, and served as CSO and head of the R & D at Hualan Biological Engineering Inc., and two years later worked as senior director and department head in USP, Shanghai. Dr. Zhu published earned his Ph.D. degree on biological sciences from UC, Irvine, M.S. degree on biochemistry from Georgetown university, and B.S. degree on chemistry from Tsinghua university.

Russia& CIS: vaccine market highlights & entry models

Vaccine Innovation Forum 2023
Privalova Arina
Director, Strategic Development, Nanolek
Arina Privalova is responsible for Strategy and Business Development at Nanolek, a Russian pharmaceutical company founded in 2011. The company specializes in the prevention and treatment of socially significant diseases and was recognized as a backbone enterprise of the Russian economy in 2020. In 2021, Nanolek was listed as one of the "50 Fastest Growing Companies in Russia." With over four years of experience at Nanolek and a background in consulting and market research in the pharmaceutical industry for over nine years, Arina's main responsibility is to ensure the continuous extension of the company's pipeline by recruiting new products via in-licensing, M&A, and commercialization deals. At VIF 2023, Arina will present an overview of the Russian vaccine market and the cooperation opportunities available with Nanolek.

Networking Lunch

Moderator

Vaccine Innovation Forum 2023
Alex Li
COO, Axter Therapeutics
Dr. Alex Li is the COO and Head of research for Axter Therapeutics Inc. Since its establishment at the end of 2021, the Axter mRNA platform has developed a number of highly efficient LNP delivery systems with independent intellectual property rights, including immune system-targeted LNP for preclinical research of mRNA tumor vaccines and antiviral vaccines. Dr. Alex Li is a Board Director of the Sino-American Pharmaceutical Professional Association (SAPA), former President of SAPA-NE, and Visiting Professor of the Chinese Academy of Medical Sciences (Peking Union Medical College). He worked in Biogen for 17 years (2000-2017), participating in the research and development of 6 new approved drugs, including the evaluation, licensing-in and lead research of the first successful anti-sense oligo drug Spinraza for Biogen. Prior to joining Axter, Dr. Li received his MBA and Ph.D. in molecular biology from the University of Tennessee, Knoxville.

Convacell – second generation vaccine against COVID-19

Vaccine Innovation Forum 2023
Sergey Arakelov
Sci Dir., St. Petersburg Scientific Research Institute of Vaccines and Sera, FMBA,RU
South Ural University, New York, NY. Master of Business Administration, 2002. Institute of Virology, Moscow, Russia. PhD (in Virology), 1988. Moscow Pedagogical University, Moscow, Russia. Master of Science, 1980. IVANOVSKY INSTITUTE OF VIROLOGY, Moscow, Russia Research Scientist (1980-1989), Laboratory Supervisor (1989-1990) NEW YORK UNIVERSITY MEDICAL CENTER, New York, New York Associate Research Scientist (1990-1994) SPECIALITY LABORATORIES, Santa Monica, California Research Scientist (1996-1998) FOCUS TECHNOLOGIES (former MRL), Cypress, California Senior Scientist (1998-2001) UNITED STATES GOVERNMENT (Center For Disease Control and Prevention), Project Manager - Consultant (2001-2003) PATHWAY DIAGNOSTICS, Malibu, California Director, Assay Development (2003-2007) INDEPENDANT CONSULTANT, Santa Monica, California (2007 - 2009) INTERNATIONAL VACCINE INSTITUTE (IVI), Seoul, Korea Laboratory Coordinator (2009-2011) FGUP SPbNIIVS FMBA RUSSIA, S-Petersburg, Russian Federation Adviser to Director of Institute (2013 - 2020) Scientific Director (2020 – present) Analytical research and scientific management of a new product development, intellectual property conceptualization, international collaboration.

Plant-based vaccine development

Vaccine Innovation Forum 2023
Jompong Champaiboon
COO,Baiya Phytopharm
Jompong is an engineer who graduated from Chulalongkorn University. He co-founded the Baiya Phytopharm in 2018 and currently serves as its Chief Operating Officer. He has a vision to promote pharmaceutical endeavors and create health security in Thailand, and he oversees the businessmanagement and operations of Baiya. He also works closely with the research team, led by Dr. Waranyoo Poolcharoen, to scale-up production from the lab scale to a larger scale. He has designed a production facility for plant-produced vaccines and biologics, which can produce up to 60 million doses of COVID-19 vaccine per year. His leadership and dedication to his work were evident in the construction of the facility. He oversaw the facility's construction and ensured that it was up and running within eight months. His hard work and commitment paid off, as the facility became the first cGMP plant-produced vaccines and biologics facility for humans in Asia. Jompong's success in his work has been driven by his passion and vision for creating health security in Thailand. He continues to work towards this goal, using his engineering skills and business acumen to make a difference in the world.

Targeted LNP in cancer vaccine development

Vaccine Innovation Forum 2023
Alex Li
COO, Axter Therapeutics
Dr. Alex Li is the COO and Head of research for Axter Therapeutics Inc. Since its establishment at the end of 2021, the Axter mRNA platform has developed a number of highly efficient LNP delivery systems with independent intellectual property rights, including immune system-targeted LNP for preclinical research of mRNA tumor vaccines and antiviral vaccines. Dr. Alex Li is a Board Director of the Sino-American Pharmaceutical Professional Association (SAPA), former President of SAPA-NE, and Visiting Professor of the Chinese Academy of Medical Sciences (Peking Union Medical College). He worked in Biogen for 17 years (2000-2017), participating in the research and development of 6 new approved drugs, including the evaluation, licensing-in and lead research of the first successful anti-sense oligo drug Spinraza for Biogen. Prior to joining Axter, Dr. Li received his MBA and Ph.D. in molecular biology from the University of Tennessee, Knoxville.

Structure-based vaccine development

Vaccine Innovation Forum 2023
Shaowei Li
Professor, Xiamen University
Shaowei Li Ph.D. Professor of Biochemistry and Structural Vaccinology, Xiamen University Shaowei Li is a tenured Professor of Biochemistry and Structural Vaccinology in the School of Life Sciences with a joint appointment in the School of Public Health, Xiamen University, China. He is the vaccine group leader in the National Institute of Diagnostics and Vaccine Development in infectious diseases (NIDVD), one of the academic leaders in the State Key Laboratory of Molecular Vaccinology and Diagnostics, deputy director in Fujian provincial Xiang An biomedicine laboratory. Dr. Li has inter-disciplinary research interests focusing on structural vaccinology, resulting in more than 120 peer-reviewed papers. He also has translational experience in vaccine development against infectious diseases—such as Hepatitis E vaccine and HPV vaccine, especially in aspects of immunogen design, process development and antigen characterization. Dr. Li has won two of China’s National Science and Technology Awards and been listed in the Top 20 translational researchers of 2016, ranked by Nature Biotechnology. He has served on the Product Development for Vaccines Advisory Committee (PDVAC), World Health Organization (WHO) since 2022.

Challenges and opportunities for novel mRNA therapy development 

Vaccine Innovation Forum 2023
Xiangrong Song
Co-Founder, Westgene
Xiangrong Song is a full professor at Sichuan University and a pharmaceutical scientist at National Key Laboratory of Biotherapy. The Song lab has developed the targeted delivery systems for gene drugs and small molecules to treat tumors, atherosclerosis, ocular diseases, infection or brain diseases. Two novel drug candidates (IND) have been approved for phase I clinical trials. She has authored more than 100 papers and is an inventor of more than 50 issued / pending patents worldwide. The technologies that Dr. Song and her colleagues have developed formed the basis for the launch of 2 biotechnology companies. The two companies are translating the aforementioned academic innovations toward commercialization and societal impact. In 2019, she was a recipient of the first prize of Science and Technology Award in Chinese National Medicine Association, for the research on immune function of Yi nationality's medicine. In 2022, she was named as the elite of science and technology in China.

Panel discussion: The future of vaccine development

Vaccine Innovation Forum 2023
Jompong Champaiboon
COO,Baiya Phytopharm
Jompong is an engineer who graduated from Chulalongkorn University. He co-founded the Baiya Phytopharm in 2018 and currently serves as its Chief Operating Officer. He has a vision to promote pharmaceutical endeavors and create health security in Thailand, and he oversees the businessmanagement and operations of Baiya. He also works closely with the research team, led by Dr. Waranyoo Poolcharoen, to scale-up production from the lab scale to a larger scale. He has designed a production facility for plant-produced vaccines and biologics, which can produce up to 60 million doses of COVID-19 vaccine per year. His leadership and dedication to his work were evident in the construction of the facility. He oversaw the facility's construction and ensured that it was up and running within eight months. His hard work and commitment paid off, as the facility became the first cGMP plant-produced vaccines and biologics facility for humans in Asia. Jompong's success in his work has been driven by his passion and vision for creating health security in Thailand. He continues to work towards this goal, using his engineering skills and business acumen to make a difference in the world.
Vaccine Innovation Forum 2023
Shaowei Li
Professor, Xiamen University
Shaowei Li Ph.D. Professor of Biochemistry and Structural Vaccinology, Xiamen University Shaowei Li is a tenured Professor of Biochemistry and Structural Vaccinology in the School of Life Sciences with a joint appointment in the School of Public Health, Xiamen University, China. He is the vaccine group leader in the National Institute of Diagnostics and Vaccine Development in infectious diseases (NIDVD), one of the academic leaders in the State Key Laboratory of Molecular Vaccinology and Diagnostics, deputy director in Fujian provincial Xiang An biomedicine laboratory. Dr. Li has inter-disciplinary research interests focusing on structural vaccinology, resulting in more than 120 peer-reviewed papers. He also has translational experience in vaccine development against infectious diseases—such as Hepatitis E vaccine and HPV vaccine, especially in aspects of immunogen design, process development and antigen characterization. Dr. Li has won two of China’s National Science and Technology Awards and been listed in the Top 20 translational researchers of 2016, ranked by Nature Biotechnology. He has served on the Product Development for Vaccines Advisory Committee (PDVAC), World Health Organization (WHO) since 2022.
Vaccine Innovation Forum 2023
Xiangrong Song
Co-Founder, Westgene
Xiangrong Song is a full professor at Sichuan University and a pharmaceutical scientist at National Key Laboratory of Biotherapy. The Song lab has developed the targeted delivery systems for gene drugs and small molecules to treat tumors, atherosclerosis, ocular diseases, infection or brain diseases. Two novel drug candidates (IND) have been approved for phase I clinical trials. She has authored more than 100 papers and is an inventor of more than 50 issued / pending patents worldwide. The technologies that Dr. Song and her colleagues have developed formed the basis for the launch of 2 biotechnology companies. The two companies are translating the aforementioned academic innovations toward commercialization and societal impact. In 2019, she was a recipient of the first prize of Science and Technology Award in Chinese National Medicine Association, for the research on immune function of Yi nationality's medicine. In 2022, she was named as the elite of science and technology in China.
Vaccine Innovation Forum 2023
Alex Li
COO, Axter Therapeutics
Dr. Alex Li is the COO and Head of research for Axter Therapeutics Inc. Since its establishment at the end of 2021, the Axter mRNA platform has developed a number of highly efficient LNP delivery systems with independent intellectual property rights, including immune system-targeted LNP for preclinical research of mRNA tumor vaccines and antiviral vaccines. Dr. Alex Li is a Board Director of the Sino-American Pharmaceutical Professional Association (SAPA), former President of SAPA-NE, and Visiting Professor of the Chinese Academy of Medical Sciences (Peking Union Medical College). He worked in Biogen for 17 years (2000-2017), participating in the research and development of 6 new approved drugs, including the evaluation, licensing-in and lead research of the first successful anti-sense oligo drug Spinraza for Biogen. Prior to joining Axter, Dr. Li received his MBA and Ph.D. in molecular biology from the University of Tennessee, Knoxville.
Vaccine Innovation Forum 2023
Sergey Arakelov
Sci Dir., St. Petersburg Scientific Research Institute of Vaccines and Sera, FMBA,RU
South Ural University, New York, NY. Master of Business Administration, 2002. Institute of Virology, Moscow, Russia. PhD (in Virology), 1988. Moscow Pedagogical University, Moscow, Russia. Master of Science, 1980. IVANOVSKY INSTITUTE OF VIROLOGY, Moscow, Russia Research Scientist (1980-1989), Laboratory Supervisor (1989-1990) NEW YORK UNIVERSITY MEDICAL CENTER, New York, New York Associate Research Scientist (1990-1994) SPECIALITY LABORATORIES, Santa Monica, California Research Scientist (1996-1998) FOCUS TECHNOLOGIES (former MRL), Cypress, California Senior Scientist (1998-2001) UNITED STATES GOVERNMENT (Center For Disease Control and Prevention), Project Manager - Consultant (2001-2003) PATHWAY DIAGNOSTICS, Malibu, California Director, Assay Development (2003-2007) INDEPENDANT CONSULTANT, Santa Monica, California (2007 - 2009) INTERNATIONAL VACCINE INSTITUTE (IVI), Seoul, Korea Laboratory Coordinator (2009-2011) FGUP SPbNIIVS FMBA RUSSIA, S-Petersburg, Russian Federation Adviser to Director of Institute (2013 - 2020) Scientific Director (2020 – present) Analytical research and scientific management of a new product development, intellectual property conceptualization, international collaboration.
Speakers
  • Executive Vice President, The Wistar Institute/ Director, Vaccine & Immunotherapy Center /Professor & WW Smith Distinguished Chair in Cancer /Research  Professor Emeritus, University of Pennsylvania,US.David Weiner
    David Weiner
    Executive Vice President, The Wistar Institute/ Director, Vaccine & Immunotherapy Center /Professor & WW Smith Distinguished Chair in Cancer /Research Professor Emeritus, University of Pennsylvania,US.
    Dr. David Weiner directs a translational research laboratory at The Wistar Institute in the area of Molecular Immunology. His group is one of the pioneering research teams in establishing the field of DNA vaccines and immunotherapies. Important reports from his lab include the first DNA vaccine studied for HIV as well as for cancer immunotherapy, the early development of DNA encoded genetic adjuvants including the particularly relevant IL-12, advances in gene optimization, and advances in electroporation (EP) technologies resulting in improved gene delivery among others. His group worked with collaborators to become the first to move DNA technology into human study. His laboratory’s work helped revitalize the field through advancement of new synthetic DNA design and modification of EP delivery approaches resulting in potent immune induction as well as the first successful Phase IIb DNA efficacy study (for HPV immunotherapy) in humans. Dr. Weiner is the recipient of numerous honors including election as a fellow to both the American Association for the Advancement of Science in 2011 and the International Society for Vaccines in 2012. He is the recipient of the NIH Director’s Transformative Research Award and received the Vaccine Industry Excellence Award for Best Academic Research Team in 2015 at the World Vaccine Congress. Weiner was honored with the prestigious Hilleman Lectureship in 2015 at the Children’s Hospital of Philadelphia Grand Rounds session and received a Stone Family Award from Abramson Cancer Center for his groundbreaking work on DNA vaccines for cancer immunotherapy. In 2019, Dr. Weiner was honored with the Scientific Achievement Award from Life Sciences PA (LSPA). Dr. Weiner returned to Wistar in 2016 from his position at The University of Pennsylvania School of Medicine as professor of Pathology and Laboratory Medicine. From 1990 to 1993, Weiner held a joint position as assistant professor of Pathology and Laboratory Medicine at The Wistar Institute and the University of Pennsylvania School of Medicine. Dr. Weiner is a co-founder of Inovio Pharmaceuticals and is a member of the Board of Directors. Dr. Weiner graduated with a B.S. in biology from SUNY at Stony Brook, N.Y., a M.S. in biology from the University of Cincinnati and a Ph.D. in developmental biology from the University of Cincinnati College of Medicine.
  • Chief Scientific Adviser, AdvacccineBin Wang
    Bin Wang
    Chief Scientific Adviser, Advacccine
    Dr. Bin Wang is the Co-founder, Chairman of Advaccine Biotechnology Co LTD. He is also holding a distinguished professor position at the Fudan University School of Basic Medical Sciences and serves as the chairman for the Nucleic Acid Vaccines branch of the Chinese Vaccine Society. His research area is focused on the effects of therapeutic vaccination to activate T cells and the mechanism of immune regulations. He has developed novel adjuvants and recombinant vaccines, novel DNA vaccine delivery, and led to several developed vaccines being tested in human clinical trials. He received his Ph.D. from the Cincinnati Children's Hospital at the University of Cincinnati School of Medicine in 1990. He completed his postdoc training in virology and immunology at the Wistar Institute in 1992 in Philadelphia. He became an instructor and assistant professor at the University of Pennsylvania Medical School from 1993 to 1998. He was a professor and served as the Chairman of the Department of Microbiology and Immunology for six years at the College of Biological Sciences, China Agricultural University before he joined Fudan University. He was one of the very early DNA vaccine technology inventors in the 90’s and performed the first-in-human DNA vaccine trials in 1994-1996. He has been involved in several clinical trials of therapeutic vaccines against chronic HBV infections in recent years and invented a novel prophylactic RSV vaccine currently under clinical phase II testing. He has published over 160 peer-review articles and awarded 35 US and 30 Chinese patents. He serves as an editorial board member for several international journals and executive member in several professional societies.
  • CTO, Lemonex, KoreaDal-Hee Min
    Dal-Hee Min
    CTO, Lemonex, Korea
    Dal-Hee Min is currently co-founder & CTO of Lemonex and Professor at Seoul National University. She received her Ph.D in Chemistry from University of Chicago. After post-doctoral research at MIT, she started her academic carrier at KAIST (Korea) as an Assistant Professor in 2007 and moved to Seoul National University in 2011. Her research focuses on drug delivery systems with collective understanding on nano-surface chemistry and diverse biomedical applications of nanomaterials including mRNA vaccines and gene therapies. She received various prestigious awards including ‘KCS-Wiley Young Chemist Award’, ‘Korea L’Oreal UNESCO Fellowship Award for Women in Science’ and ‘Order of Science and Technological Merit (Do-Yak Medal)’ from Korea Government. She is actively involved in many global activities. For highlighted activities, she gave two invited talks at World Economic Forum in 2018 where she introduced DegradaBALL technology-‘Miniaturizing Biotechnology’ in sessions ‘Bio-Inspired Drug Delivery’ and ‘Harnessing Nature for Technology ‘. She also gave talks about drug delivery platform technology at mRNA health conference, PODD, JP Morgan and BIO USA. Focus Area: mRNA vaccine / gene therapy / Nanobiotechnology / Nanomedicine/ Drug Delivery / Immunotherapy
  • EX-VP, RNA Formulation&Drug Delivery, BioNtechHeinrich Hass
    Heinrich Hass
    EX-VP, RNA Formulation&Drug Delivery, BioNtech
    Heinrich Haas, Department of Biopharmaceutics and Pharmaceutical Technology Johannes Gutenberg-Universität, Mainz Mainz, Germany. Ph.D. in the group of Prof. Dr. Helmuth Möhwald at Johannes-Gutenberg Universität Mainz. Researched lipid membranes and organized bio-molecular systems. In pharmaceutical industry (Munich Biotech, Medigene, BioNTech) developed different types of nanoparticle products to clinical stage. Focus on advanced approaches for nanoparticle development and control.
  • Academician, PI, Institute of Process, CASGuanghui Ma
    Guanghui Ma
    Academician, PI, Institute of Process, CAS
    Guanghui Ma is a professor of the State Key Laboratory of Biochemical Engineering (SKLBCE), Institute of Process Engineering (IPE). She is an academician of CAS in China and AIMBE fellow. She is serving as Director of the State Key Laboratory of Biochemical Engineering. She received Bachelor degree from Gunma University, Master and PhD degrees from Tokyo Institute of Technology, respectively. She joined SKLBCE as a professor in 2001 and was promoted to the director in 2012. Her research interests focus on the preparation of uniform microspheres and microcapsules and their applications in biochemical engineering and biomedicine engineering, such as biochemical separation media, drug carriers, vaccine adjuvants (vaccine delivery systems), microcarriers for cell culture, and enzyme immobilization carriers. She has published over 500 papers, including Nat. Mater., Nat. Nanotechnol. Nat. Biomed. Eng., Nat. Commun., Sci. Adv., JACS, Adv. Mater., etc. She has more than 90 patents authorized, the technology and products have been commercialized in companies, and have been used in more than 500 affiliations in the world. She has received the State National Invention Award (2nd Class; 2009), the Beijing Science and Technology Award (1st Class; 2005), the Basic Research Achievement Award (1st Class prise of Science and Technology Award; 2020) of the Chemical Industry and Engineering Society of China, and Natural Science Award (1st Class; 2020) of the Chinese Society of Particuology.
  • Sci Dir., St. Petersburg Scientific Research Institute of Vaccines and Sera, FMBA,RUSergey Arakelov
    Sergey Arakelov
    Sci Dir., St. Petersburg Scientific Research Institute of Vaccines and Sera, FMBA,RU
    South Ural University, New York, NY. Master of Business Administration, 2002. Institute of Virology, Moscow, Russia. PhD (in Virology), 1988. Moscow Pedagogical University, Moscow, Russia. Master of Science, 1980. IVANOVSKY INSTITUTE OF VIROLOGY, Moscow, Russia Research Scientist (1980-1989), Laboratory Supervisor (1989-1990) NEW YORK UNIVERSITY MEDICAL CENTER, New York, New York Associate Research Scientist (1990-1994) SPECIALITY LABORATORIES, Santa Monica, California Research Scientist (1996-1998) FOCUS TECHNOLOGIES (former MRL), Cypress, California Senior Scientist (1998-2001) UNITED STATES GOVERNMENT (Center For Disease Control and Prevention), Project Manager - Consultant (2001-2003) PATHWAY DIAGNOSTICS, Malibu, California Director, Assay Development (2003-2007) INDEPENDANT CONSULTANT, Santa Monica, California (2007 - 2009) INTERNATIONAL VACCINE INSTITUTE (IVI), Seoul, Korea Laboratory Coordinator (2009-2011) FGUP SPbNIIVS FMBA RUSSIA, S-Petersburg, Russian Federation Adviser to Director of Institute (2013 - 2020) Scientific Director (2020 – present) Analytical research and scientific management of a new product development, intellectual property conceptualization, international collaboration.
  • VP, Cansino BiologicsChunlin Xin
    Chunlin Xin
    VP, Cansino Biologics
    Mr. Chunlin Xin is the Vice President of CanSino Biologics, where he currently oversees External R&D and scientific affairs. With over 20 years of experience in the biotech industry, Mr. Xin previously served as the Oncology Biomarker technical leader at the Novartis BioMedical Research Institute in the United States and China. He has also worked as a technical officer at the National Research Institute of Canada and as a senior scientist at the Merck Canada Research Institute. Mr. Xin graduated from the Virology Institute at the CDC China and spent five years as a visiting scholar at the University of North Carolina in the United States. In 2017, he joined CanSino as Senior Director of R&D, where he was responsible for designing and developing new vaccines and exploring and establishing new technology platforms. Most recently, Mr. Xin has played a lead role in assisting many developing countries in establishing COVID-19 vaccine manufacturing facilities through tech transfer.
  • COO,Baiya PhytopharmJompong Champaiboon
    Jompong Champaiboon
    COO,Baiya Phytopharm
    Jompong is an engineer who graduated from Chulalongkorn University. He co-founded the Baiya Phytopharm in 2018 and currently serves as its Chief Operating Officer. He has a vision to promote pharmaceutical endeavors and create health security in Thailand, and he oversees the businessmanagement and operations of Baiya. He also works closely with the research team, led by Dr. Waranyoo Poolcharoen, to scale-up production from the lab scale to a larger scale. He has designed a production facility for plant-produced vaccines and biologics, which can produce up to 60 million doses of COVID-19 vaccine per year. His leadership and dedication to his work were evident in the construction of the facility. He oversaw the facility's construction and ensured that it was up and running within eight months. His hard work and commitment paid off, as the facility became the first cGMP plant-produced vaccines and biologics facility for humans in Asia. Jompong's success in his work has been driven by his passion and vision for creating health security in Thailand. He continues to work towards this goal, using his engineering skills and business acumen to make a difference in the world.
  • Director, Strategic Development, NanolekPrivalova Arina
    Privalova Arina
    Director, Strategic Development, Nanolek
    Arina Privalova is responsible for Strategy and Business Development at Nanolek, a Russian pharmaceutical company founded in 2011. The company specializes in the prevention and treatment of socially significant diseases and was recognized as a backbone enterprise of the Russian economy in 2020. In 2021, Nanolek was listed as one of the "50 Fastest Growing Companies in Russia." With over four years of experience at Nanolek and a background in consulting and market research in the pharmaceutical industry for over nine years, Arina's main responsibility is to ensure the continuous extension of the company's pipeline by recruiting new products via in-licensing, M&A, and commercialization deals. At VIF 2023, Arina will present an overview of the Russian vaccine market and the cooperation opportunities available with Nanolek.
  • Professor, Xiamen UniversityShaowei Li
    Shaowei Li
    Professor, Xiamen University
    Shaowei Li Ph.D. Professor of Biochemistry and Structural Vaccinology, Xiamen University Shaowei Li is a tenured Professor of Biochemistry and Structural Vaccinology in the School of Life Sciences with a joint appointment in the School of Public Health, Xiamen University, China. He is the vaccine group leader in the National Institute of Diagnostics and Vaccine Development in infectious diseases (NIDVD), one of the academic leaders in the State Key Laboratory of Molecular Vaccinology and Diagnostics, deputy director in Fujian provincial Xiang An biomedicine laboratory. Dr. Li has inter-disciplinary research interests focusing on structural vaccinology, resulting in more than 120 peer-reviewed papers. He also has translational experience in vaccine development against infectious diseases—such as Hepatitis E vaccine and HPV vaccine, especially in aspects of immunogen design, process development and antigen characterization. Dr. Li has won two of China’s National Science and Technology Awards and been listed in the Top 20 translational researchers of 2016, ranked by Nature Biotechnology. He has served on the Product Development for Vaccines Advisory Committee (PDVAC), World Health Organization (WHO) since 2022.
  • President& General Manager, MaxvaxDexiang Chen
    Dexiang Chen
    President& General Manager, Maxvax
    Dexiang Chen, Doctor of Immunology, Mississippi State University, has been engaged in the development of vaccines and vaccine adjuvants in Pfizer, Novartis and PATH scientific and technological organizations for more than 30 years, and has presided over a number of major international public health special projects funded by international organizations, foundations and national governments. Among the more than 20 infectious disease vaccine development projects presided over and participated in, many products have been listed globally. Dr. Chen Dexiang has published more than 60 vaccine-related academic papers in world-class academic journals such as Science and Nature Medicine.
  • Partner, Rothwell FiggDan Shores
    Dan Shores
    Partner, Rothwell Figg
    Dan Shores is a Partner at Rothwell Figg and a founder of its Boston, Massachusetts office. He has an extensive background in IP law in the biotech space and has been practicing in that space during the entirely of his 17-year career including in matters relating to small molecules, biosimilars, mRNA, LNP, and oligonucleotide technologies. Dan is passionate about helping his clients build robust patent portfolios, litigate matters (both as plaintiffs and defendants in the U.S. District Courts and in IPR and other post-grant proceedings), protect trade secrets, negotiate strategic collaborations, conduct due diligence and landscape investigations, and prepare for success in funding rounds and exits. Dan is a problem-solver who excels at deciphering key translational aspects of a broad array of technologies to maximize leverage in the context of clients’ desired implementation of such technologies whether as participants in dynamic markets or as first movers. Dan is a registered patent attorney licensed to practice before the U.S. Patent and Trademark Office. He is a member of the bars of the Supreme Court of the United States, United States Court of Appeals for the Federal Circuit, and United States District Court for the District of Massachusetts.
  • CSO China, Immorna BiotherapeuticsYuanqing Liu
    Yuanqing Liu
    CSO China, Immorna Biotherapeutics
    Dr. Liu Yuanqing graduated from Shanghai Medical College of Fudan University and was a surgeon at Shanghai Zhongshan Hospital. He completed his PhD in Vrije Universiteit Brussel in Belgium and was one of the pioneers on myeloid-derived suppressors in tumors. He was previously a senior research lead at Sanofi Pasteur French headquarter, where he contributed to various vaccine projects, including cancer vaccines, vaccines against infectious diseases, pediatric vaccines, adjuvants, etc. Dr. Liu is an industry veteran with extensive experience in the development of innovative vaccines for international market. He was a member of the EU Innovative Medicine Initiative. Since 2021, he has been the Chief Scientific Officer of Immorna Biotechnology. He is based in Shanghai where Immorna has established a high-standard R&D site aiming to accelerate the development of mRNA vaccines and drugs in China.
  • CSO, Hilleman LaboratoriesAlain Bouckenooghe
    Alain Bouckenooghe
    CSO, Hilleman Laboratories
    Dr Alain Bouckenooghe is currently the Chief Scientific Officer at Hilleman Laboratories where he is leading the R&D department of this biotech company. He has been working in the pharmaceutical industry over 20 years, mostly in vaccine R&D but also in regulatory and medical affairs. Alain obtained his Medical Degree at the Catholic University of Leuven, Belgium. Upon graduation as MD he worked for several years in a rural assignment as a District Medical Officer under the Ministry of Health of Zambia. Subsequently, he completed his residency in Internal Medicine at the University of Texas, Houston. He has a Master of Public Health degree from the UT School of Public Health, Houston TX, and completed a Fellowship in Adult Infectious Diseases at Baylor College of Medicine, Houston TX. Alain held several academic positions during this time in the Department of Medicine at Baylor College. After initial industry experience with MSD and GlaxoSmithKline Biologicals, he joined Sanofi Pasteur in December 2006 to 2018, covering various responsibilities over time, including Regional Head of Clinical R&D Asia Pacific, Regional Head Medical Affairs, and R&D Partnership lead in Asia. Alain joined MSD in 2018 as Associate VP leading the respiratory franchise in Global Clinical Development. Alain feels very fortunate and honoured to be part of the Hilleman Laboratories team aiming to provide effective and affordable solutions for Global Health problems especially those impacting lower and middle income countries.
  • PI, The Institute of Microbiology, CASLianpan Dai
    Lianpan Dai
    PI, The Institute of Microbiology, CAS
    Lianpan Dai, PhD, Principal Investigator at Institute of Microbiology, Chinese Academy of Sciences. He received his doctor's degree from Technical University of Munich (TUM), Germany. His research is mainly focused on the design and development of novel vaccines against major pathogens and the mechanism of protective immune response. Important research and translational achievements have been made in the research and development of vaccines against coronaviruses, Zika virus and other emerging infectious diseases, among which the recombinant protein subunit COVID-19 vaccine has been approved for use in many countries. The results are published as first/corresponding authors in the journals including Cell, The New England Journal of Medicine, Nature Immunology, Nature Reviews Immunology, Cell Host & Microbe. He is supported by the National Science Fund for Excellent Young Scholars, and is the winner of VCANBIO Award for Biosciences and Medicine, excellent member of the Innovation Promotion Association of Chinese Academy of Sciences, and the Young Scholar Award of Chinese Society of Immunology.
  • Co-Founder&CTO, StemirnaHaifa Shen
    Haifa Shen
    Co-Founder&CTO, Stemirna
    Dr. Shen Haifa is co-founder and CTO of StemiRNA Therapeutics. He received his PhD degree from the Graduate School of Biomedical Sciences, the University of Texas/ M D Anderson Cancer Center in 1997, and completed his post-doctoral training at National Cancer Institute in 2001. He then joined the biopharmaceutical industry and worked there for eight years on cancer drug discovery and development. He went back to academia afterwards, focusing his research on drug design and drug delivery platforms. Dr. Shen was professor at Houston Methodist Hospital and founding director of the Innovative Therapeutics program at Houston Methodist Cancer Center, Weill Cornell Medical College of Cornell University. Dr. Shen and his group have published more than 110 peer-reviewed research articles including those in Nature, Nature Biotechnology, and Science Immunology, and have over 10 patents and patent applications.
  • Co-Founder, WestgeneXiangrong Song
    Xiangrong Song
    Co-Founder, Westgene
    Xiangrong Song is a full professor at Sichuan University and a pharmaceutical scientist at National Key Laboratory of Biotherapy. The Song lab has developed the targeted delivery systems for gene drugs and small molecules to treat tumors, atherosclerosis, ocular diseases, infection or brain diseases. Two novel drug candidates (IND) have been approved for phase I clinical trials. She has authored more than 100 papers and is an inventor of more than 50 issued / pending patents worldwide. The technologies that Dr. Song and her colleagues have developed formed the basis for the launch of 2 biotechnology companies. The two companies are translating the aforementioned academic innovations toward commercialization and societal impact. In 2019, she was a recipient of the first prize of Science and Technology Award in Chinese National Medicine Association, for the research on immune function of Yi nationality's medicine. In 2022, she was named as the elite of science and technology in China.
  • Director of Chula Vaccine Research Center, Chulalongkorn UniversityKiat Ruxrungtham
    Kiat Ruxrungtham
    Director of Chula Vaccine Research Center, Chulalongkorn University
    Kiat Ruxrungtham, is a Professor of Medicine, Department of Medicine , Faculty of Medicine, Chulalongkorn University; and Scientific Chair of the Chula Vaccine Research Center (ChulaVRC); and Director of the Covid19 Vaccine Development Program, ChulaVRC. He is providing teaching and patient care on Allergy -Clinical Immunology and HIV Medicine at the King Chulalongkorn Memorial Hospital, Faculty of Medicine, Chulalongkorn University; and is mentoring junior researchers on HIV medicine at HIVNAT, TRCARC; vaccine and Immunology (at Chula Vaccine Research Center); and also on clinical trials. He is currently leading the Chula-Covid19 mRNA vaccine development program at ChulaVRC. Honors: He has received several awards: 2006 Outstanding Internist Award on Medical Academy, Royal College of Physicians, Thailand 2007 Outstanding Researcher Award, and the Highest Citation Award, Chulalongkorn University, Bangkok, Thailand 2011 Senior Research Scholar Award, the Thailand Research Fund 2011 Outstanding Researcher Award, National Research Council, Thailand 2015 Senior Research Scholar Award, the Thailand Research Fund 2015 Outstanding Research Award, the Thailand Research Fund 2022 A Royal Award “Contributors to the development of the country’s vaccines” from Her Royal Highness Princess Maha Chakri Sirindhorn at the 10th Vaccination Conference Publications: He has published more than 370 peer review papers on HIV, immunology, allergy, and vaccine. Contributions to national and international academics and professional organization: 1. Former President of the Allergy, Asthma and Immunology Association, Thailand (AAIAT) 2. Former President of the Thai AIDS Society (TAS) 3. Co-chair of the Co-chair of the APAACI and APAAAPARI 2018, Bangkok, Thailand 4. Co-chair of the World Allergy Congress 2023, Bangkok, Thailand 5. Chief-editor, Asian Pacific Journal of Allergy and Immunology (APJAI)
  • CEO, Ruizhou BioJeff Zhu
    Jeff Zhu
    CEO, Ruizhou Bio
    Dr. Jeff Zhu is the founder and CEO of Shanghai Reinovax Biologics co., Ltd., a fast-growing biotech company focusing on discovery and development of innovative vaccines and other biologics. Dr. Zhu has over 20 years’ industrial experience on discovery and development of small molecules, recombinant proteins, antibodies and vaccines from the early discovery to clinical trials. He played an important role in moving multiple drug candidates from the initiation to the clinical trial stage during his 13-year tenure at Pfizer’s R & D center in San Diego. Dr. Zhu moved back to China in 2011, and served as CSO and head of the R & D at Hualan Biological Engineering Inc., and two years later worked as senior director and department head in USP, Shanghai. Dr. Zhu published earned his Ph.D. degree on biological sciences from UC, Irvine, M.S. degree on biochemistry from Georgetown university, and B.S. degree on chemistry from Tsinghua university.
  • Professor, Sun Yat-sen UniversityYongming Chen
    Yongming Chen
    Professor, Sun Yat-sen University
    Yongming Chen received his Ph.D. on polymer science in 1993 from Nankai University. From 1994 to 1998, he was Postdoctoral Researcher and later Research Assistant at the Institute of Chemistry, CAS. Then he spent the period 1998−2001 as Postdoctoral Researcher in University of Düsseldorf and University of Mainz. Since 2001, Chen was Professor at the Institute of Chemistry CAS. He moved to Sun Yat-sen University in 2013. He obtained “Distinguished Young Scholars” by National Science Foundation of China (2006). He served for Polymer, an Elsevier journal, as an Associate Editor during 2007 to 2018. He also was in Advisory Board Panel of Macromolecules and ACS Macro Letters, the ACS Publication. Professor Chen’s research interests are in the areas of biomaterials chemistry and biomaterials application in delivery of proteins and nucleic acids, specifically application in immune attenuation. He has published over 260 research articles in Science Advances, Nature Communication, Biomaterials, Nano Letters et al and obtained 10 more licenced patents.
  • COO, Axter TherapeuticsAlex Li
    Alex Li
    COO, Axter Therapeutics
    Dr. Alex Li is the COO and Head of research for Axter Therapeutics Inc. Since its establishment at the end of 2021, the Axter mRNA platform has developed a number of highly efficient LNP delivery systems with independent intellectual property rights, including immune system-targeted LNP for preclinical research of mRNA tumor vaccines and antiviral vaccines. Dr. Alex Li is a Board Director of the Sino-American Pharmaceutical Professional Association (SAPA), former President of SAPA-NE, and Visiting Professor of the Chinese Academy of Medical Sciences (Peking Union Medical College). He worked in Biogen for 17 years (2000-2017), participating in the research and development of 6 new approved drugs, including the evaluation, licensing-in and lead research of the first successful anti-sense oligo drug Spinraza for Biogen. Prior to joining Axter, Dr. Li received his MBA and Ph.D. in molecular biology from the University of Tennessee, Knoxville.
  • Director of International regulatory Affairs, Sinovac BiotechTianping Wang
    Tianping Wang
    Director of International regulatory Affairs, Sinovac Biotech
    Tianping WANG, graduated from Renmin University of China with a master's degree, Director of International Regulatory Affairs, Group Quality Department Manager of Sinovac Biotech Ltd. Leading person in passing WHO PQ/EUL for four vaccines and obtaining nearly 300 international regulatory approvals in more than 40 countries for multiple vaccines. Coauthor of WHO Vaccine Prequalification Guidance. Responsible for promoting key projects such as COVID-19 overseas clinical trials and technical licensing, and participating in drawing the blueprint of international development strategy for Sinovac.
  • CEO & President of AbMax BiotechnologyLe Sun
    Le Sun
    CEO & President of AbMax Biotechnology
    Dr. Sun, CEO & President of AbMax Biotechnology, Inc., Thousand Talent of Beijing, Adjunct Prof. of Beijing Normal University. He received his PhD in biochemistry from Tsinghua Univ. in 1989 and finished his postdoctoral study in Dr. David Barnes’s lab at Oregon State Univ. He has more than 30 yrs experience in antibody-based research and drug development. He was Director of R& D at Upstate Biotechnology Inc., a market leader in the research reagent sector. In 2000, as co-founder and the President, he started A&G Pharmaceutical in Baltimore, created the record of “Generation of mAb in 28 days” and received $2.5 M investment from MedImmune in 2001. In 2004, he started Welson Pharmaceuticals working on antibody drug conjugate, now has one leading candidate in co-development with a Chinese Pharma. In 2006, he started AbMax as a Biotech CRO, established the largest collection of mAbs against infectious diseases. Using AbEpiMax, the ONLY B cell-epitope identification program, and AbADCCZero, IP-protected De-ADCC technology, his team is developing 15+ Bio-Betters of Block-burst antibody drugs for I/O and auot-immune diseases. He has published 40+ papers on journals such as Nature Med., Nature Genetics, Immunity, Development Cell, etc.
  • General Manager of Vaccine Clinical Center, CSPC GroupYuanzheng Qiu
    Yuanzheng Qiu
    General Manager of Vaccine Clinical Center, CSPC Group
    Dr. Qiu is the General Manager of Vaccine Clinical Center of CSPC Group. He joined the vaccine industry in 2005 and has been engaged in vaccine early stage R&D, clinical research and medical affairs for nearly 18 years. He has served in Beijing Institute of Biological Products, Sinovac Biotech, GlaxoSmithKline, Sanofi Pasteur, Merck Sharp & Dohme and Fosun Pharmaceuticals, where he was responsible for the early development of pneumococcal conjugate vaccine and Hib vaccine, and registration clinical trials with human avian influenza vaccine (H5N1), influenza A/H1N1 vaccine, DTaP-based combined vaccines, meningococcal conjugate vaccine, MMR varicella combined vaccine, polio inactivated vaccine, rotavirus vaccine, HPV vaccine, and SARS-CoV-2 mRNA vaccine. He was also responsible for the post-marketing clinical research and medical support for various vaccines. He is now working for CSPC Group and is responsible for the clinical studies of the vaccine product line.
  • Global BD Director, Aptar PharmaNektaria Karavas
    Nektaria Karavas
    Global BD Director, Aptar Pharma
    Nektaria Karavas is the Global Director of Business Development for Nasal Vaccines, Antivirals and Immuno-stimulants at Aptar Pharma. Ms. Karavas joined Aptar Pharma in 2004 and has held various commercial roles executing long-term strategy within key customer and global accounts in North America focusing on nasal drug delivery. She has contributed to multiple nasal development programs, supported commercial scale up and product launches for New Drug Applications (NDA) using an Aptar delivery device for key pharmaceutical clients across different therapeutic indications. Nektaria holds a Bachelor of Science from McGill University, Montreal, Canada
  • Vice President of Scientific Affairs, Aptar PharmaJulie D. Suman
    Julie D. Suman
    Vice President of Scientific Affairs, Aptar Pharma
    Dr. Julie D. Suman is the Vice President of Scientific Affairs for Aptar Pharma. She manages strategic scientific planning and Aptar’s Scientific Advisory Board. Dr. Suman is also the co-founder of Next Breath. She holds a B.S. in Pharmacy from Duquesne University (1996) and a Ph.D. in Pharmaceutical Sciences from the University of Maryland, Baltimore (2002). Dr. Suman serves on the External Advisory Committee of the New South Wales RNA Production and Research Network. In addition, she is a co-editor for Respiratory Drug Delivery Proceedings, an international symposium, and an an Affiliate Assistant Professor in the Department of Pharmaceutics, School of Pharmacy, Virginia Commonwealth University. Dr. Suman is the Past-Chair of the AAPS Inhalation Technology Focus Group. Dr. Suman is also a member of the Parental Drug Association Visible Particulate Taskforce. She is a licensed Maryland pharmacist. Dr. Suman has published her research in peer-reviewed journals and has been presented during podium sessions at international meetings, the FDA Topics in Bioequivalence Seminar Series and has been an invited speaker at ANVISA in Brazil. Dr. Suman’s doctoral research, which focused on the relationship between in vitro tests for nasal sprays and in vivo deposition, has been recognized for excellence by a research award presented at the International Society for Aerosols in Medicine, 2001. In 2008, Dr. Suman received an award from the Greater Baltimore Committee for Entrepreneurial Spirit.
  • COO and Head of research,Axter TherapeuticsAlex Li
    Alex Li
    COO and Head of research,Axter Therapeutics
    Dr. Alex Li is the COO and Head of research for Axter Therapeutics Inc. Since its establishment at the end of 2021, the Axter mRNA platform has developed a number of highly efficient LNP delivery systems with independent intellectual property rights, including immune system-targeted LNP for preclinical research of mRNA tumor vaccines and antiviral vaccines. Dr. Alex Li is a Board Director of the Sino-American Pharmaceutical Professional Association (SAPA), former President of SAPA-NE, and Visiting Professor of the Chinese Academy of Medical Sciences (Peking Union Medical College). He worked in Biogen for 17 years (2000-2017), participating in the research and development of 6 new approved drugs, including the evaluation, licensing-in and lead research of the first successful anti-sense oligo drug Spinraza for Biogen. Prior to joining Axter, Dr. Li received his MBA and Ph.D. in molecular biology from the University of Tennessee, Knoxville.
  • SVP, Head of China Research and External Collaboration, Clover BiopharmaceuticalWei Tan
    Wei Tan
    SVP, Head of China Research and External Collaboration, Clover Biopharmaceutical
    Dr. Tan is responsible for drug discovery, preclinical development, translation research and external collaboration in China. Dr. Tan got his Ph.D. in Molecular Medicine from UT Health Science Center San Antonio and received his Postdoctoral training with Dr. Michael Karin at UC San Diego. Dr. Tan worked in Pfizer and Novartis for 9 years, specialized in drug discovery and translational research, bridging preclinical research to early clinical trials. Dr. Tan worked at Biosion Biotech and Coherent Biopharma before he joined Clover. Dr. Tan was selected as Jiangsu Innovation and Entrepreneur Talent and Suzhou Innovation and Entrepreneur Leading Talent.
  • Organizer
    Meeting Venue

    Fenda International Hotel Beijing

    北京丰大国际大酒店

    NO. 20, Middle Ronghua Rd, Daxing District, Beijing China

    北京市大兴区荣华中路20号

    Tel: 86-10-67518888 


    Registration
    Preparation Stage
    Registration
    End of Event
    Choose ticket
    Type
    Price(¥)
    Sales End
    Quantity
    Standard Tickets
    3,280
    2023-06-30 15:50
    Past Events

    Refund Description:No Refund
    pls kindly notice that refund will not be available, you could arrange other colleagues to join if you cannot show.

    Price
    0
    Partners
    1729374621808170.jpg1729374701808170.jpg


    1729375131808170.png


    1729375891808170.png1729376451808170.png
    1729376211808170.png1729377001808170.jpg1729377571808170.png0957501051808170.png